All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 EGFR mutation Ex19del EGFR mutation L858R Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES previous systemic treatment (%) previous systemic treatment NO (%) smoker (current or former) smoker (never) stage I stage II stage IIIa
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), ... vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ADAURA (stage II-IIIA), 2020 0.40 [0.09; 1.80]
AURA3, 2017 0.87 [0.64; 1.18]
CAURAL (EXPLORATORY), 2019 (REV) 0.38 [0.06; 2.54]
FLAURA, 2018 0.63 [0.45; 0.88]
Nie, 2018 0.79 [0.38; 1.63]
0.74 [0.60 ; 0.91 ] ADAURA (stage II-IIIA), 2020, AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), FLAURA, 2018, Nie, 2018 5 0% 1,833 moderate not evaluable progression or deaths (PFS)detailed results AURA3, 2017 0.30 [0.22; 0.40]
CAURAL (EXPLORATORY), 2019 (REV) 0.91 [0.18; 4.64]
FLAURA, 2018 0.46 [0.37; 0.57]
Nie, 2018 0.23 [0.13; 0.41]
0.35 [0.24 ; 0.51 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), FLAURA, 2018, Nie, 2018 4 69% 1,151 moderate not evaluable RFS/DFSdetailed results ADAURA (Stage IB to IIIA), 2020 0.20 [0.14; 0.29]
0.20 [0.14 ; 0.29 ] ADAURA (Stage IB to IIIA), 2020 1 0% 682 NA not evaluable DCRdetailed results AURA3, 2017 3.85 [2.18; 6.82]
FLAURA, 2018 2.92 [1.28; 6.68]
3.52 [2.20 ; 5.64 ] AURA3, 2017, FLAURA, 2018 2 0% 975 moderate not evaluable events or deaths (EFS)detailed results ADAURA (stage II-IIIA), 2020 0.17 [0.11; 0.26]
0.17 [0.11 ; 0.26 ] ADAURA (stage II-IIIA), 2020 1 0% 682 NA not evaluable objective responses (ORR)detailed results AURA3, 2017 5.39 [3.45; 8.43]
CAURAL (EXPLORATORY), 2019 (REV) 2.22 [0.42; 11.83]
FLAURA, 2018 1.27 [0.85; 1.90]
Nie, 2018 17.33 [6.66; 45.11]
4.04 [1.27 ; 12.87 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), FLAURA, 2018, Nie, 2018 4 92% 1,151 moderate not evaluable AE (any grade)detailed results ADAURA (Stage IB to IIIA), 2020 4.97 [2.28; 10.85]
AURA3, 2017 0.34 [0.04; 2.83]
CAURAL (EXPLORATORY), 2019 (REV) 0.70 [0.01; 37.74]
FLAURA, 2018 1.01 [0.32; 3.16]
1.41 [0.37 ; 5.45 ] ADAURA (Stage IB to IIIA), 2020, AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), FLAURA, 2018 4 67% 1,680 moderate not evaluable AE (grade 3-4)detailed results AURA3, 2017 0.31 [0.20; 0.48]
CAURAL (EXPLORATORY), 2019 (REV) 0.08 [0.01; 0.77]
FLAURA, 2018 0.67 [0.47; 0.95]
0.39 [0.18 ; 0.84 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), FLAURA, 2018 3 79% 1,000 moderate not evaluable AE leading to death (grade 5)detailed results ADAURA (Stage IB to IIIA), 2020 0.51 [0.02; 15.20]
AURA3, 2017 1.96 [0.22; 17.74]
CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
FLAURA, 2018 0.59 [0.21; 1.64]
0.73 [0.31 ; 1.76 ] ADAURA (Stage IB to IIIA), 2020, AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), FLAURA, 2018 4 0% 1,680 low not evaluable AE leading to treatment discontinuation (any grade)detailed results ADAURA (Stage IB to IIIA), 2020 4.11 [2.01; 8.40]
FLAURA, 2018 0.71 [0.45; 1.13]
1.67 [0.30 ; 9.31 ] ADAURA (Stage IB to IIIA), 2020, FLAURA, 2018 2 94% 1,236 low not evaluable SAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.61 [0.12; 3.16]
FLAURA, 2018 0.81 [0.55; 1.20]
0.80 [0.54 ; 1.17 ] CAURAL (EXPLORATORY), 2019 (REV), FLAURA, 2018 2 0% 585 low not evaluable STRAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 (REV) 3.00 [0.09; 97.33]
3.00 [0.09 ; 97.33 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable TRAE (any grade)detailed results AURA3, 2017 0.60 [0.32; 1.11]
CAURAL (EXPLORATORY), 2019 (REV) 0.43 [0.08; 2.42]
FLAURA, 2018 0.42 [0.29; 0.60]
0.46 [0.34 ; 0.62 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), FLAURA, 2018 3 0% 1,000 low not evaluable TRAE (grade 3-4)detailed results AURA3, 2017 0.12 [0.06; 0.22]
CAURAL (EXPLORATORY), 2019 (REV) 0.14 [0.01; 2.97]
0.12 [0.07 ; 0.22 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 444 moderate not evaluable TRAE leading to death (grade 5)detailed results Nie, 2018 0.99 [0.02; 50.39]
0.99 [0.02 ; 50.39 ] Nie, 2018 1 0% 147 NA not evaluable Arthralgia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Back pain AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Constipation AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Cough AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 1.02 [0.02; 51.45]
CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.20 [0.07 ; 19.77 ] ADAURA (Stage IB to IIIA), 2020, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 709 moderate not evaluable Decreased appetite AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 4.09 [0.18; 91.02]
4.09 [0.18 ; 91.02 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 1.02 [0.02; 51.45]
1.02 [0.02 ; 51.45 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Diarrhoea AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 8.32 [1.03; 66.86]
CAURAL (EXPLORATORY), 2019 (REV) 0.70 [0.02; 22.54]
3.61 [0.36 ; 35.93 ] ADAURA (Stage IB to IIIA), 2020, CAURAL (EXPLORATORY), 2019 (REV) 2 30% 709 moderate not evaluable Dry skin AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 2.04 [0.07; 60.97]
CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.76 [0.13 ; 23.39 ] ADAURA (Stage IB to IIIA), 2020, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 709 moderate not evaluable Dyspnoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Nausea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Neutropenia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.33 [0.01; 7.94]
0.33 [0.01 ; 7.94 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Pneumonia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.33 [0.01; 7.94]
0.33 [0.01 ; 7.94 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Pruritus AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 1.02 [0.02; 51.45]
CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.20 [0.07 ; 19.77 ] ADAURA (Stage IB to IIIA), 2020, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 709 moderate not evaluable Rash AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Stomatitis AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 12.42 [0.69; 223.20]
CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
5.91 [0.57 ; 61.41 ] ADAURA (Stage IB to IIIA), 2020, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 709 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-06 05:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 431
